#xbb_2_3 — Public Fediverse posts

Here's the latest variant picture for New South Wales, Australia.

The EG.5.* "Eris" variant (40%) has become dominant. XBB.2.3.* "Acrux" (23%) is also rising.

#COVID19 #Australia #NSW #Sydney #EG_5 #Eris #XBB_2_3 #Acrux @auscovid19
🧵

Here's the latest variant picture for New South Wales, Australia.

"Deltacron" XBC.* (23%) is rising sharply to challenge the dominance of XBB.1.16.* "Arcturus" (29%).

XBB.2.3.* "Acrux" (15%) is also rising quite rapidly.

The mix of very different variants poses a raised immediate re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volumes seem representative up to June 19.

#COVID19 #Australia #NSW #Sydney #XBC #Deltacron #XBB_2_3 #Acrux #XBB_1_16 #Arcturus @auscovid19
🧵

Here's the latest variant picture for Kenya.

XBB.1.22.* "Bellatrix" (48%) clan has been dominant recently, led by the FY.4 sub-lineage.

There was a rise in XBB.2.3.* "Acrux" (41%) clan in late May, led by the GE.1 sub-lineage.

The sample volumes are a bit sparse and patchy.

#COVID19 #Kenya #XBB_1_22 #Bellatrix #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for Singapore.

XBB.2.3.* "Acrux" (33%) and XBB.1.16.* "Arcturus" (30%) are battling for dominance.

XBB.1.9.* "Hyperion" (23%) has rebounded during May.

Be alert for conjunctivitis symptoms, particularly associated with the Arcturus variant.

The vigorous mix of very different variants poses a raised immediate re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volumes seem representative up to May 23.

#COVID19 #Singapore #XBB_1_16 #Arcturus #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for Malaysia.

XBB.1.16.* "Arcturus" (39%) now looks dominant over XBB.1.9.* "Hyperion" (22%).

XBB.2.3.* "Acrux" (11%) is rising, and might be the next to challenge.

Be alert for conjunctivitis symptoms, particularly associated with the Arcturus variant.

The mix of very different variants poses a raised immediate re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volumes seem representative up to May 18, but look a bit patchy.

#COVID19 #Malaysia #XBB_1_16 #Arcturus #XBB_1_9 #Hyperion #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for Vietnam.

XBB.1.16.* "Arcturus" (60%) has remained dominant.

XBB.1.9.* "Hyperion" (26%) looks like challenging next.

XBB.2.3.* "Acrux" (13%) is also rising.

Be alert for conjunctivitis symptoms, particularly associated with the Arcturus variant.

The mix of very different variants poses a raised immediate re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volume has declined, and the available data is only up to May 7.

#COVID19 #Vietnam #XBB_1_16 #Arcturus #XBB_1_5 #Kraken #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for New Zealand. The sample volumes seem representative up to May 18.

XBB.1.16.* "Arcturus" (28%) has been growing steadily and now appears dominant, displacing CH.1.1.* "Orthrus" (23%).

Be alert for conjunctivitis symptoms, which seem more common with the "Arcturus" variant, although it's wave has likely peaked already by now.

XBB.1.5.* "Kraken" (19%) and XBB.1.9.* "Hyperion" (15%) are both significant.

XBB.2.3.* "Acrux" (9%) is starting to rise

The vigorous mix of variants implies increased immediate reinfection risks, for those relying on immunity from a prior infection.

#COVID19 #NZ #XBB_1_16 #Arcturus #CH_1_1 #Orthrus #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for New Zealand. The sample volumes seem representative up to May 18.

XBB.1.16.* "Arcturus" (28%) has been growing steadily and now appears dominant, displacing CH.1.1.* "Orthrus" (23%).

Be alert for conjunctivitis symptoms, which seem more common with the "Arcturus" variant, although it's wave has likely peaked already by now.

XBB.1.5.* "Kraken" (19%) and XBB.1.9.* "Hyperion" (15%) are both significant.

XBB.2.3.* "Acrux" (9%) is starting to rise

The vigorous mix of variants implies increased immediate reinfection risks, for those relying on immunity from a prior infection.

#COVID19 #NZ #XBB_1_16 #Arcturus #CH_1_1 #Orthrus #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for New Zealand. The sample volumes seem representative up to May 18.

XBB.1.16.* "Arcturus" (28%) has been growing steadily and now appears dominant, displacing CH.1.1.* "Orthrus" (23%).

Be alert for conjunctivitis symptoms, which seem more common with the "Arcturus" variant, although it's wave has likely peaked already by now.

XBB.1.5.* "Kraken" (19%) and XBB.1.9.* "Hyperion" (15%) are both significant.

XBB.2.3.* "Acrux" (9%) is starting to rise

The vigorous mix of variants implies increased immediate reinfection risks, for those relying on immunity from a prior infection.

#COVID19 #NZ #XBB_1_16 #Arcturus #CH_1_1 #Orthrus #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for New Zealand. The sample volumes seem representative up to May 18.

XBB.1.16.* "Arcturus" (28%) has been growing steadily and now appears dominant, displacing CH.1.1.* "Orthrus" (23%).

Be alert for conjunctivitis symptoms, which seem more common with the "Arcturus" variant, although it's wave has likely peaked already by now.

XBB.1.5.* "Kraken" (19%) and XBB.1.9.* "Hyperion" (15%) are both significant.

XBB.2.3.* "Acrux" (9%) is starting to rise

The vigorous mix of variants implies increased immediate reinfection risks, for those relying on immunity from a prior infection.

#COVID19 #NZ #XBB_1_16 #Arcturus #CH_1_1 #Orthrus #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for New Zealand. The sample volumes seem representative up to May 18.

XBB.1.16.* "Arcturus" (28%) has been growing steadily and now appears dominant, displacing CH.1.1.* "Orthrus" (23%).

Be alert for conjunctivitis symptoms, which seem more common with the "Arcturus" variant, although it's wave has likely peaked already by now.

XBB.1.5.* "Kraken" (19%) and XBB.1.9.* "Hyperion" (15%) are both significant.

XBB.2.3.* "Acrux" (9%) is starting to rise

The vigorous mix of variants implies increased immediate reinfection risks, for those relying on immunity from a prior infection.

#COVID19 #NZ #XBB_1_16 #Arcturus #CH_1_1 #Orthrus #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for China.

XBB.1.9.* "Hyperion" (45%) is still dominant dominant.

XBB.1.16.* "Arcturus" (25%) looks like challenging next.

New clans XBB.1.22.* "Bellatrix" (9%) and XBB.2.3.* "Acrux" (8%) are beginning to rise.

The vigorous mix of very different variants raises the re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volumes seem representative up to May 10.

#COVID19 #China #XBB_1_9 #Hyperion #XBB_1_16 #Arcturus #XBB_1_22 #Bellatrix #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for Singapore.

XBB.1.16.* "Arcturus" (39%) appears to have surged to dominance displacing XBB.2.3.* "Acrux" (25%).

Be alert for conjunctivitis symptoms, particularly associated with Arcturus variant.

The vigorous mix of very different variants poses a raised immediate re-infection risk for anyone relying on natural immunity from a recent infection.

The sample volumes seem representative up to May 9.

#COVID19 #Singapore #XBB_1_16 #Arcturus #XBB_2_3 #Acrux

Interactive genomic sequencing dataviz, code, acknowledgements and more info here:
https://github.com/Mike-Honey/covid-19-genomes#readme

Here's the latest variant picture for the XBB.2.3.* "Acrux" variant clan.

First, an animated map showing the spread of the XBB.2.3.* "Acrux" variant around the world. The earliest samples were found in mid-December in both Karnataka India and Delaware USA, so the origin is somewhat unclear. Singapore became another significant hub.

Locations are approximate - typically country and state/province.

Here's a link to the video file - feel free to share anywhere:
https://github.com/Mike-Honey/covid-19-genomes/raw/main/covid-19-genomes-map-XBB-2-3-Acrux.mp4

#COVID19 #India #USA #Singapore #XBB_2_3 #Acrux
🧵

Here's the latest variant picture for Singapore:

XBB.1.5 "Kraken" (23%) is still dominant, but looks to have peaked.

The strongly growing lineages are XBB.2.3 (19%) and XBB.1.16 "Arcturus" (18%), with XBB.1.16 looking to have the faster growth.

XBB.1.9.1 "Hyperion" (13%) appears to be past it's peak.

Recent samples look representative, up to March 25.

#COVID19 #Singapore #XBB_1_5 #Kraken #XBB_1_16 #Arcturus #XBB_2_3
🧵